Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke

Launched by THE FIRST HOSPITAL OF JILIN UNIVERSITY · Aug 15, 2017

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called alprostadil for patients who have experienced an acute ischemic stroke, which is a type of stroke caused by a blockage of blood flow to the brain. The goal is to see how well alprostadil can help improve recovery compared to a placebo (a treatment that does not contain the active medication). Researchers will look at patients' progress over 90 days to see if alprostadil helps them regain function and improve their quality of life.

To be eligible for this trial, participants need to be between 18 and 75 years old, have a confirmed diagnosis of ischemic stroke, and should not have major health issues like certain heart conditions or bleeding disorders. Participants will be asked to voluntarily sign an informed consent form, and they will be monitored closely throughout the study. This trial is not yet recruiting participants, but it aims to contribute valuable information about stroke treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. ischemic stroke diagnosed by CT or MRI
• • 2. Age: 18-75 years
• • 3. Pre-stroke mRS score is 0-1
• • 4. within 72 hours symptoms onset
• • 5. 4 ≤ NIHSS \<20
• • 6. Patient is willing to participate voluntarily and to sign a written patient informed consent
• Exclusion Criteria:
• • 1. intracranial tumors, encephalitis or lesions diagnosed by CT or MRI
• • 2. patients with thrombolytic therapy
• • 3. low platelet , blood system diseases or other bleeding tendency
• • 4. suspected subarachnoid hemorrhage or aortic dissection coma
• • 5. atrial fibrillation, myocardial infarction, heart valve disease, infective endocarditis, heart rate \<50 beats / min
• • 6. ALT or AST continued to rise more than 3 times the upper limit of normal creatinine clearance rate\<30ml/min
• • 7. Dementia and mental illness
• • 8. Patient who is participating in other trials or has been participated in other trials in recent 3 months